A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
A phase 3 trial of Nivolumab, Ipilimumab in renal cell carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.
Overview
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer is a phase 3 interventional study registered as NCT03873402 by Bristol-Myers Squibb, with 437 participants enrolled, started 2019-06-21 and due to reach its primary completion in 2027-03-11. Interventions recorded: Nivolumab, Ipilimumab, Ipilimumab placebo. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance
Shares Bristol Myers Squibb, Nivolumab, Renal cell carcinoma.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal
Shares Ipilimumab, Bristol Myers Squibb, Renal cell carcinoma.
- TrialStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab.
- TrialEffectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Shares Bristol Myers Squibb, Nivolumab.
- TrialA Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Shares Bristol Myers Squibb, Nivolumab.
- TrialA Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- TrialCOSMIC-313
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.